According to a recent report from Reuters, Pfizer is set to reap massive financial benefits from their vaccine sales as the company becomes the preferred jab.
According to the first-quarter results published by Pfizer this week, its coronavirus jab has racked up revenues of $3.5bn for the biopharma giant in the first three months of 2021.
The financial results also revealed that Pfizer has vastly exceeded its Covid-19 vaccine sales forecast of $15bn, and now expects the jab to bring in over $30bn of revenue in 2021 – an increase of 73% on previously anticipated figures.
“Pfizer Inc raised its 2021 sales forecast for its COVID-19 vaccine by 29% to $33.5 billion and said it believes people will need a third dose of the shot developed with German partner BioNTech to keep protection against the virus high.
The company said it could apply for an emergency use authorization (EUA) for a booster dose as early as August.”
Pfizer is also apparently working on treatments for COVID-19, while over 700 studies already show there are several extremely successful FDA-approved treatments currently on the market.
Pfizer has been extremely aggressive in trying to protect the details of its international COVID19 vaccine agreements. However, one of their contracts has allegedly leaked.
The leaked agreement was from the government of Albania, and it not only covers the manufacturing of vaccines, but also for “any device, technology, or product used in the administration.
The agreement shows that countries are not permitted to escape their contract, which states that even if a drug will be found to treat COVID19 the contract cannot be voided.
Many Twitter users claim that this is why Ivermectin and other treatments, that have been scientifically proven to be successful, have been suppressed by governments and the media.
Countries are also not permitted to return the product, for any reason.
“Pfizer will not, in any circumstances, accept any returns of Product (or any dose)…no Product returns may take place under any circumstances.”
The document also reveals that the country of Albania was paying $12 per dosage for approximately 250K units.
A top Pfizer exec said in February that the drugmaker aims to charge more after the “pandemic pricing environment,” and an influential analyst says the company could be eying prices 3 to 4 times higher.
On an earnings call earlier this month, Chief Financial Officer Frank D’Amelio said that “obviously,” the company is “going to get more on price” after the “pandemic pricing environment.”
D’Amelio explained that Pfizer expects its COVID vaccine margins to improve. Under one pandemic supply deal, Pfizer was charging the U.S. $19.50 per dose, over $7 more per dose than Albania is paying.
Countries also have no right “to withhold, offset, recoup or debit any amounts owed to Pfizer, whether under this Agreement or otherwise, against any other amount owed (or to become due and owing) to it by Pfizer or a Pfizer Affiliate.”
The agreement addresses the potential long-term effects and efficiency.
“Purchaser acknowledges…the long-term effects and efficacy of the Vaccine are not currently known and that there may be adverse effects of the Vaccine that are not currently known.”
The contract also states that countries can not hold Pfizer accountable if any should go wrong with the vaccines, and if any lawsuits arise governments must defend Pfizer and pay for their defense.
“Purchaser hereby agrees to indemnify, defend and hold harmless Pfizer, BioNTech (and) their Affiliates…from and against any and all suits, claims, actions, demands, losses, damages, liabilities, settlements, penalties, fines, costs and expenses…”
“(Pfizer) shall notify Purchaser of Losses for which it is seeking indemnification… Upon such notification, Purchaser shall promptly assume conduct and control of the defense of such Indemnified Claims on behalf of (Pfizer)”
However, “Pfizer shall have the right to assume control of such defense… and Purchaser shall pay all Losses, including, without limitation, the reasonable attorneys’ fees and other expenses incurred.”
The contract must be kept confidential for 10 years according to the agreement.
“The provisions of this Section 10 (Confidential Information) shall survive the termination or expiration of this Agreement for a period of ten (10) years”